The Rift Valley Fever virus protein NSm and putative cellular protein interactions

Virology Journal

Göran Bucht¹  Clas Ahlm²  Lena Lindgren²  Jonas Näslund²  Cecilia Engdahl² 

[1] Swedish Defence Research Agency, SE-90182, Umeå, Sweden;Department of Clinical Microbiology, Umeå University, SE-90187, Umeå, Sweden

关键词: Cpsf2;    Ppil2;    SNAP-25;    Yeast two-hybrid;    NSm;    Rift Valley fever;   

Others  :  1154310
DOI  :  10.1186/1743-422X-9-139

 received in 2012-01-27, accepted in 2012-07-17,  发布年份 2012

【 摘 要 】

Rift Valley Fever is an infectious viral disease and an emerging problem in many countries of Africa and on the Arabian Peninsula. The causative virus is predominantly transmitted by mosquitoes and high mortality and abortion rates characterize outbreaks in animals while symptoms ranging from mild to life-threatening encephalitis and hemorrhagic fever are noticed among infected humans. For a better prevention and treatment of the infection, an increased knowledge of the infectious process of the virus is required.

The focus of this work was to identify protein-protein interactions between the non-structural protein (NSm), encoded by the M-segment of the virus, and host cell proteins. This study was initiated by screening approximately 26 million cDNA clones of a mouse embryonic cDNA library for interactions with the NSm protein using a yeast two-hybrid system.

We have identified nine murine proteins that interact with NSm protein of Rift Valley Fever virus, and the putative protein-protein interactions were confirmed by growth selection procedures and β-gal activity measurements. Our results suggest that the cleavage and polyadenylation specificity factor subunit 2 (Cpsf2), the peptidyl-prolyl cis-trans isomerase (cyclophilin)-like 2 protein (Ppil2), and the synaptosome-associated protein of 25 kDa (SNAP-25) are the most promising targets for the NSm protein of the virus during an infection.

【 授权许可】

   
2012 Engdahl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Daubney R, Garnham P: Enzootic hepatitis of Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 1931, 34:8922-8926.
• [2]Meegan JM: The Rift Valley fever epizootic in Egypt 1977–78. 1. Description of the epizzotic and virological studies. Trans R Soc Trop Med Hyg 1979, 73:618-623.
• [3]Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, Al-Mazrou Y, Khan AS, Rollin PE, Swanepoel R, Ksiazek TG, Nichol ST: Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000–01. Emerg Infect Dis 2002, 8:1415-1420.
• [4]Coetzer JA: The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 1977, 44:205-211.
• [5]Coetzer JA: The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res 1982, 49:11-17.
• [6]Jost CC, Nzietchueng S, Kihu S, Bett B, Njogu G, Swai ES, Mariner JC: Epidemiological assessment of the Rift Valley fever outbreak in Kenya and Tanzania in 2006 and 2007. AmJTrop Med Hyg 2010, 83:65-72.
• [7]Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, Macharia J, Ithondeka PM, Musaa J, Breiman RF, et al.: Rift Valley fever outbreak in livestock in Kenya, 2006–2007. AmJTrop Med Hyg 2010, 83:58-64.
• [8]Flick R, Bouloy M: Rift Valley fever virus. Curr Mol Med 2005, 5:827-834.
• [9]Gerdes GH: Rift Valley fever. Rev Sci Tech 2004, 23:613-623.
• [10]Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J: Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 2010, 41:61.
• [11]Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, Al-Sayed MO, Abodahish AA, Khan AS, Ksiazek TG, Shobokshi O: Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003, 37:1084-1092.
• [12]Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, Omulo S, Gikundi S, Mmbuji P, Bloland P, et al.: Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. AmJTrop Med Hyg 2010, 83:22-27.
• [13]Chevalier V, Pépin M, Plée L, Lancelot R: Rift Valley fever–a threat for Europe? Eur Surveill 2010, 15:19506.
• [14]Bouloy M, Flick R: Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antivir Res 2009, 84:101-118.
• [15]Ikegami T, Makino S: Rift valley fever vaccines. Vaccine 2009, 27(Suppl 4):D69-D72.
• [16]Elliott RM: The Bunyaviridae. Plenum Press, New York; 1996.
• [17]Swanepoel R, Burt FJ: Principles and Practice of Clinical Virology. 6th edition. John Wiley & Sons Ltd,  ; 2009.
• [18]Billecocq A, Spiegel M, Vialat P, Kohl A, Weber F, Bouloy M, Haller O: NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004, 78:9798-9806.
• [19]Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, Huerre M, Haller O: Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001, 75:1371-1377.
• [20]Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S: Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann N Y Acad Sci 2009, 1171(Suppl 1):E75-E85.
• [21]Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, Egly JM: TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004, 116:541-550.
• [22]Mansuroglu Z, Josse T, Gilleron J, Billecocq A, Leger P, Bouloy M, Bonnefoy E: Nonstructural NSs protein of rift valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J Virol 2010, 84:928-939.
• [23]Won S, Ikegami T, Peters CJ, Makino S: NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol 2006, 80:8274-8278.
• [24]Gerrard SR, Bird BH, Albariño CG, Nichol ST: The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 2007, 359:459-465.
• [25]Bird BH, Albariño CG, Nichol ST: Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007, 362:10-15.
• [26]Won S, Ikegami T, Peters CJ, Makino S: NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007, 81:13335-13345.
• [27]Narayanan A, Popova T, Turell M, Kidd J, Chertow J, Popov SG, Bailey C, Kashanchi F, Kehn-Hall K: Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection. PLoS One 2011, 6:e20354.
• [28]Fasshauer D, Antonin W, Subramaniam V, Jahn R: SNARE assembly and disassembly exhibit a pronounced hysteresis. Nat Struct Biol 2002, 9:144-151.
• [29]Hanson PI, Heuser JE, Jahn R: Neurotransmitter release - four years of SNARE complexes. Curr Opin Neurobiol 1997, 7:310-315.
• [30]Oyler GA, Higgins GA, Hart RA, Battenberg E, Billingsley M, Bloom FE, Wilson MC: The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations. J Cell Biol 1989, 109:3039-3052.
• [31]Ravichandran V, Chawla A, Roche PA: Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. J Biol Chem 1996, 271:13300-13303.
• [32]Näslund J, Lagerqvist N, Lundkvist A, Evander M, Ahlm C, Bucht G: Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J Virol Methods 2008, 151:277-282.
• [33]Smith DR, Steele KE, Shamblin J, Honko A, Johnson J, Reed C, Kennedy M, Chapman JL, Hensley LE: The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010, 407:256-267.
• [34]Ikegami T, Makino S: The Pathogenesis of Rift Valley Fever. Viruses 2011, 3:493-519.
• [35]Alrajhi AA, Al-Semari A, Al-Watban J: Rift Valley fever encephalitis. Emerg Infect Dis 2004, 10:554-555.
• [36]Stanley AC, Lacy P: Pathways for cytokine secretion. Physiology (Bethesda) 2010, 25:218-229.
• [37]Wang BB, Hayenga KJ, Payan DG, Fisher JM: Identification of a nuclear-specific cyclophilin which interacts with the proteinase inhibitor eglin c. Biochem J 1996, 314(Pt 1):313-319.
• [38]Pushkarsky T, Yurchenko V, Vanpouille C, Brichacek B, Vaisman I, Hatakeyama S, Nakayama KI, Sherry B, Bukrinsky MI: Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. J Biol Chem 2005, 280:27866-27871.
• [39]Barik S: Immunophilins: for the love of proteins. Cell Mol Life Sci 2006, 63:2889-2900.
• [40]Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M: Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol 2010, 160:305-317.
• [41]Bukrinsky MI: Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol 2002, 23:323-325.
• [42]Jenny A, Hauri HP, Keller W: Characterization of cleavage and polyadenylation specificity factor and cloning of its 100-kilodalton subunit. Mol Cell Biol 1994, 14:8183-8190.
• [43]Edmonds M: A history of poly A sequences: from formation to factors to function. Prog Nucleic Acid Res Mol Biol 2002, 71:285-389.
• [44]Danckwardt S, Hentze MW, Kulozik AE: 3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J 2008, 27:482-498.
• [45]Sall AA, Zanotto PM, Sene OK, Zeller HG, Digoutte JP, Thiongane Y, Bouloy M: Genetic reassortment of Rift Valley fever virus in nature. J Virol 1999, 73:8196-8200.
• [46]Bröms JE, Lavander M, Sjöstedt A: A conserved alpha-helix essential for a type VI secretion-like system of Francisella tularensis. J Bacteriol 2009, 191:2431-2446.
• [47]Miller JH: Experiments in Molecular Genetics. Cold Spring Harbor Laboratory, New York; 1972.